Author:
Kluz-Barłowska Marta,Kluz Tomasz,Paja Wiesław,Sarzyński Jaromir,Łączyńska-Madera Monika,Odrzywolski Adrian,Król Paweł,Cebulski Józef,Depciuch Joanna
Abstract
AbstractThe phenomenon of platinum resistance is a very serious problem in the treatment of ovarian cancer. Unfortunately, no molecular, genetic marker that could be used in assigning women suffering from ovarian cancer to the platinum-resistant or platinum-sensitive group has been discovered so far. Therefore, in this study, for the first time, we used FT-Raman spectroscopy to determine chemical differences and chemical markers presented in serum, which could be used to differentiate platinum-resistant and platinum-sensitive women. The result obtained showed that in the serum collected from platinum-resistant women, a significant increase of chemical compounds was observed in comparison with the serum collected from platinum-sensitive woman. Moreover, a decrease in the ratio between amides vibrations and shifts of peaks, respectively, corresponding to C–C/C–N stretching vibrations from proteins, amide III, amide II, C = O and CH lipids vibrations suggested that in these compounds, structural changes occurred. The Principal Component Analysis (PCA) showed that using FT-Raman range, where the above-mentioned functional groups were present, it was possible to differentiate the serum collected from both analyzed groups. Moreover, C5.0 decision tree clearly showed that Raman shifts at 1224 cm−1 and 2713 cm−1 could be used as a marker of platinum resistance. Importantly, machine learning methods showed that the accuracy, sensitivity and specificity of the FT-Raman spectroscopy were from 95 to 100%.
Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. Höhn, A. K. et al. 2020 WHO classification of female genital tumors. Geburtshilfe Frauenheilkd 81, 1145–1153 (2021).
2. Ferlay, J. et al. Cancer statistics for the year 2020: An overview. Int. J. Cancer 149, 778–789 (2021).
3. Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2021. CA Cancer J. Clin. 71, 7–33 (2021).
4. Arora, T., Mullangi, S. & Lekkala, M. R. Ovarian cancer. In StatPearls (eds Arora, T. et al.) (StatPearls Publishing, 2023).
5. Dasari, S. & Bernard Tchounwou, P. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur. J. Pharmacol. 740, 364–378 (2014).